Physician profile
Michael Duben
NPI 1972523959
$3,455.93
in general payments reported to CMS, 2019-2025
25 companies · $422 in 2025
The $422 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $477 · 2020: $249 · 2021: $622 · 2022: $620 · 2023: $471 · 2024: $594 · 2025: $422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,487.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,160.64 | 2019-2025 | Evenity, Prolia, Prolia |
| Lilly USA, LLC | $183.06 | 2019-2024 | Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $176.97 | 2019-2024 | Farxiga |
| Radius Health, INC. | $138.72 | 2019-2024 | Tymlos |
| Abbvie INC. | $89.32 | 2019-2023 | Synthroid |
| Esperion Therapeutics, INC. | $89.23 | 2021-2024 | Nexletol |
| Abbott Laboratories | $80.90 | 2021-2023 | Freestyle Libre 3 |
| Novo Nordisk INC | $61.34 | 2023-2025 | Wegovy |
| Ascendis Pharma Endocrinology INC | $49.51 | 2024-2025 | Yorvipath |
| Horizon Therapeutics Plc | $46.62 | 2023 | Tepezza |
| Bayer Healthcare Pharmaceuticals INC. | $46.57 | 2021-2022 | |
| Medtronic, INC. | $42.21 | 2022-2023 | Minimed 780g |
| Dexcom, INC. | $35.06 | 2021-2025 | Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $34.97 | 2020 | |
| Astellas Pharma US INC | $27.65 | 2024 | Veozah |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $26.41 | 2025 | Jubbonti |
| Tandem Diabetes Care, INC. | $25.73 | 2022 | |
| Ascend Therapeutics US, LLC | $24.62 | 2022 | |
| Sanofi-Aventis U.S. LLC | $23.75 | 2022 | |
| Alvogen INC | $18.87 | 2022 | |
| Ibsa Pharma INC. | $16.91 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.00 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.95 | 2019 | |
| Cequr Corporation | $13.50 | 2022 | |
| Merck Sharp & Dohme LLC | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Duben listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.